Clinical implications of microRNAs in liver cancer stem cells

Stella Chai¹ and Stephanie Ma¹,²

Abstract
The prognosis of patients diagnosed with hepatocellular carcinoma (HCC) is often dismal, mainly due to late presentation, high recurrence rate, and frequent resistance to chemotherapy and radiotherapy. Accumulating evidence on the differential microRNA (miRNA) expression patterns between non-tumor and HCC tissues or between liver cancer stem cells (CSCs) and non-CSC subsets and the significant clinical implications of these differences suggest that miRNAs are a promising, non-invasive marker for the prognosis and diagnosis of the disease. This perspective article summarizes the current knowledge of miRNAs in liver CSCs and highlights the need for further investigations of the role of miRNAs in regulating liver CSC subsets for possible future clinical applications.

Key words: MicroRNA, liver cancer stem cells, hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the most common form of liver cancer, representing 80% of all cases[1]. The disease is the sixth most common and third most deadly cancer worldwide[2]. The prognosis of patients diagnosed with HCC is often dismal, mainly due to the late presentation, high recurrence rate, and frequent resistance to chemotherapy and radiotherapy[3]. Current available serum biomarkers, such as alpha-fetoprotein (AFP) and des-gamma carboxy prothrombin (DCP), are insufficient. Thus, there is an urgent need to identify additional sensitive and specific biomarkers, especially markers that can also serve as possible therapeutic targets for the disease[4].

In the past decade, the concept of the cancer stem cell (CSC) or tumor-initiating cell (T-IC) has been vigorously investigated, with encouraging results that suggest a new direction in cancer treatment. In contrast to the abundant non-tumorigenic cancer cells, CSCs comprise a small subset of cancer cells within a tumor that exhibit both stem cell-like and cancer cell-like characteristics, including the abilities to self-renew and to initiate tumor formation[5-7]. There is now evidence to show that CSCs represent a subset of cells that are more resistant to conventional therapy and thus serve as the origin of the entire tumor. Therapies that specifically target these cells, which are believed to be pivotal for the growth and maintenance of the entire tumor mass, may result in a more durable response and even in a cure for the disease. Liver CSCs were first identified as a side population (SP) in 2006[8] and subsequently further characterized to express specific cell surface markers including CD133[9-11], CD90[12], CD44[13], EpCAM (CD326)[14], and CD24[15]. Researchers have also investigated the molecular pathways that regulate this specific group of cells, and several signaling pathways related to cell proliferation and cell differentiation have been largely explored, including Wnt/β-catenin, transforming growth factor-beta (TGF-β), Hedgehog, Notch, and Myc[16].

The discovery of microRNAs (miRNAs) nearly two decades ago has shed much light on the development of cancer research. miRNAs are small non-coding RNAs that negatively regulate gene expression at the post-transcriptional level. The first identified miRNAs, lin-4 and let-7, were found to regulate stem cells in C. elegans[17,18]. In addition to regulating stem cells, miRNAs play a role in CSC self-renewal, differentiation, tumorigenesis, drug resistance, and metastasis. To date, over 1,000 human miRNAs have been identified, and hundreds of these molecules have been reported to be associated with cancerous tissues and/or body fluids or waste products from cancer patients[19]. As a result, miRNAs have been proposed to function as useful diagnostic and/or prognostic tumor markers in various cancer types[20]. Approximately 100 miRNAs have been found to be deregulated in HCC patients compared with healthy individuals[21] (Table 1). In addition, due to the stability of


| miRNA       | Sample source       | Regulation | Target                | Reference(s) |
|-------------|---------------------|------------|-----------------------|--------------|
| let-7       | Oct4⁺CD133⁺ liver CSCs | Up         | –                     | [28]         |
| miR-130b    | CD133⁺ liver CSCs    | Up         | TP53INP1              | [29]         |
| miR-145     | –                   | –          | Oct4                  | [32]         |
| miR-150     | CD133⁺ liver CSCs    | Up         | c-Myb                 | [31]         |
| miR-181     | EpCAM⁺AFP⁺ liver CSCs | Up         | CDX2, GATA6, NLK      | [25]         |
| miR-199a-3p | –                   | –          | CD44                  | [33]         |
| let-7c      | Serum               | Up         | –                     | [28]         |
| let-7f      | Serum               | Up         | –                     | [28]         |
| miR-1       | Serum               | Up         | –                     | [28]         |
| miR-15b     | Serum               | Up         | –                     | [30]         |
| miR-16      | Serum               | Down       | –                     | [41]         |
| miR-17-5p⁺ | Serum               | Up         | –                     | [42,43]      |
| miR-18a⁺    | Serum               | Up         | –                     | [44]         |
| miR-21⁺     | Serum/plasma        | Up         | –                     | [27,41,45,46]|
| miR-21 *    | Serum               | Down       | –                     | [47]         |
| miR-25      | Serum               | Up         | –                     | [28]         |
| miR-92a     | Serum               | Up         | –                     | [28]         |
| miR-130b    | Serum               | Up         | –                     | [30]         |
| miR-122⁺    | Serum               | Up         | –                     | [27,47]      |
| miR-146a⁺   | Serum               | Up         | –                     | [48]         |
| miR-183     | Serum               | Up         | –                     | [30]         |
| miR-199a-5p⁺| Serum               | Down       | –                     | [41]         |
| miR-206     | Serum               | Up         | –                     | [28]         |
| miR-215     | Serum               | Up         | –                     | [48]         |
| miR-221⁺    | Serum               | Up         | –                     | [46]         |
| miR-222⁺    | Serum               | Up         | –                     | [46,47]      |
| miR-223⁺    | Serum               | Up         | –                     | [27,47]      |
| miR-224⁺    | Serum               | Up         | –                     | [46,48]      |
| miR-375⁺    | Serum               | Up         | –                     | [28]         |
| miR-574-3p  | Serum               | Up         | –                     | [48]         |
| miR-885-5p  | Serum               | Up         | –                     | [48]         |
| miR-17-5p   | Tissue              | Up         | –                     | [43]         |
| miR-18a     | Tissue              | Up         | ESR1                  | [49]         |
| miR-19a     | Tissue              | Down       | –                     | [50]         |
| miR-21      | Tissue              | Up         | PTEN, PDCD4           | [51–53]      |
| miR-22      | Tissue              | Down       | HDAC4                 | [54]         |
| miR-23a     | Tissue              | Up         | PGC-1α, G6PC          | [55]         |
| miR-24      | Tissue              | Down       | –                     | [50]         |
| miR-26a     | Tissue              | Down       | IL-6                  | [56]         |
| miR-29      | Tissue              | Down       | Bcl-2, Mcl-1          | [57]         |
| miR-29c     | Tissue              | Down       | TNFAIP3               | [58]         |
| miR-30d     | Tissue              | Up         | GNAI2                 | [59]         |
| miR-31      | Tissue              | Up         | –                     | [51]         |
| miR-34a     | Tissue              | Down       | c-met                 | [60]         |
| miR-99a     | Tissue              | Down       | IGF-1R, mTOR, PLK1    | [61,62]      |
| miR-100     | Tissue              | Down       | PLK1                  | [62]         |
| miR-101     | Tissue              | Down       | SOX9, Mcl-1           | [63,64]      |
| miR-108b    | Tissue              | Up         | APC                   | [65]         |
| miR-122     | Tissue              | Up         | –                     | [51]         |
| miR-124     | Tissue              | Down       | ROCK2, EZH2           | [63,66]      |
| miR-125a-5p | Tissue              | Down       | MMP11, VEGF-A, SIRT7  | [67,68]      |
| miR-125b    | Tissue              | Down       | SIRT7                 | [68]         |

(To be continued)
CSCs, cancer stem cells; HCC, hepatocellular carcinoma. *miRNAs reported to have the same regulation (direction of change in expression) in both serum and tissue samples from HCC patients. **miRNAs reported to have the opposite regulation (direction of change in expression) in serum and tissue samples from HCC patients. -, information not available.

| miRNA   | Sample source | Regulation | Target                | Reference(s) |
|---------|---------------|------------|-----------------------|--------------|
| miR-126 | Tissue        | Down       | –                     | [50]         |
| miR-129-3p | Tissue       | Down       | SOX4                  | [69]         |
| miR-138 | Tissue        | Down       | CCND3                 | [70]         |
| miR-139 | Tissue        | Down       | ROCK2                 | [71]         |
| miR-140-5p | Tissue    | Down       | TGFBR1, FGF9          | [72]         |
| miR-143 | Tissue        | Up         | FNDC3B                | [73]         |
| miR-145 | Tissue        | Down       | IRS1, IRS2, IGF1R     | [51,74]      |
| miR-146a | Tissue       | Down       | –                     | [51]         |
| miR-147 | Tissue        | Up         | –                     | [50]         |
| miR-151 | Tissue        | Up         | RhoGDIA               | [75]         |
| miR-155 | Tissue        | Up         | –                     | [76]         |
| miR-182 | Tissue        | Up         | MTSS1                 | [77]         |
| miR-183 | Tissue        | Up         | PDCD4                 | [78]         |
| miR-191 | Tissue        | Up         | TIMP3                 | [79]         |
| miR-193b | Tissue       | Down       | CCND1, ETS1           | [80]         |
| miR-195 | Tissue        | Down       | Cyclin D1, CDK6, E2F3 | [81]         |
| miR-198 | Tissue        | Down       | c-met                 | [82]         |
| miR-199a-3p | Tissue     | Down       | mTOR, c-met, CD44     | [33,83]      |
| miR-199a-5p | Tissue    | Down       | DDR1                  | [83,84]      |
| miR-200c | Tissue        | Down       | –                     | [51]         |
| miR-210 | Tissue        | Up         | VMP1                  | [85]         |
| miR-214 | Tissue        | Down       | HDGF, β-catenin       | [86,87]      |
| miR-216a | Tissue       | Up         | TSLC1                 | [88]         |
| miR-219-5p | Tissue    | Down       | GPC3                  | [89]         |
| miR-221 | Tissue        | Up         | –                     | [51]         |
| miR-222 | Tissue        | Up         | –                     | [51]         |
| miR-223 | Tissue        | Down       | –                     | [50,51]      |
| miR-224 | Tissue        | Up         | CDC42, CDH1, PAK2, Bcl-2 | [90]        |
| miR-301a | Tissue       | Up         | Gax                   | [91]         |
| miR-335 | Tissue        | Down       | –                     | [92]         |
| miR-338-3p | Tissue    | Down       | Cyclin D1             | [93,94]      |
| miR-372 | Tissue        | Up         | –                     | [95]         |
| miR-373 | Tissue        | Up         | PPP6C                 | [96]         |
| miR-375 | Tissue        | Down       | AEG-1                 | [97]         |
| miR-450a | Tissue       | Down       | DNMT3a                | [98]         |
| miR-490-3p | Tissue     | Up         | ERGIC3                | [99]         |
| miR-519d | Tissue        | Up         | CDKN1A/p21, PTEN, AKT3, TIMP2 | [100] |
| miR-520b | Tissue        | Down       | MEK2, Cyclin D1       | [101]        |
| miR-520e | Tissue        | Down       | NIK                   | [102]        |
| miR-550a | Tissue        | Up         | CPEB4                 | [103]        |
| miR-602 | Tissue        | Up         | RASSF1A               | [104]        |
| miR-615-5p | Tissue    | Up         | IGF-II                | [105]        |
| miR-637 | Tissue        | Down       | LIF                   | [106]        |
| miR-650 | Tissue        | Up         | ING4                  | [107]        |
| miR-657 | Tissue        | Up         | TLE1                  | [108]        |
| miR-886-5p | Tissue    | Down       | –                     | [50]         |
miRNAs in the blood and the tissue-specific characteristics of the miRNA expression pattern, the detection of circulating miRNA levels in the serum of HCC patients is now increasingly recognized to be a promising non-invasive tool for the prognosis and diagnosis of this disease. Recently, an increasing number of studies have found altered miRNA expression in liver CSC subsets compared with non-CSC subsets or normal liver tissue (Table 1); other studies have identified various miRNAs that control the expression of liver CSC markers. Of these, miR-181, let-7, miR-130b, miR-150, miR-145, and miR-199a-3p are described in detail below. Taken together, these findings suggest that miRNAs may represent tools for the more accurate prognosis and diagnosis of HCC and may even act as potential therapeutic targets for the eradication of liver CSC subsets.

**miR-181**

Ji et al. have found that multiple members of the miR-181 family, including miR-181a, miR-181b, miR-181c, and miR-181d, are consistently up-regulated in the liver CSC subset marked with EpCAM*. AFP surface markers. In this study, the expression of miR-181 transcripts enhanced the quantity and tumorigenicity of EpCAM+ HCC cells by regulating the expression of the proliferation markers CDX2 (caudal type homeobox 2), UGT2B7 (UDP glucuronosyltransferase 2 family, polypeptide B7), and CYP3A4 (cytochrome P450, family 3, subfamily A, polypeptide 4) and the beta-catenin-related genes CCND1 (cyclin D1) and TACSTD1 (epithelial cell adhesion molecule, EpCAM). Further, miR-181s maintained stemness by directly targeting GATA6 (GATA-binding protein 6) and CDX2 (caudal type homeobox 2) to block cell differentiation and NLK (nemo-like kinase) to activate the Wnt/β-catenin pathway. In addition, the expression of miR-181 transcripts was directly induced upon activation of the Wnt/β-catenin pathway and was inhibited upon its inactivation. This study defined a novel regulatory link between miR-181s and human EpCAM+ liver CSCs and implied that the molecular targeting of miR-181 may be used to eradicate HCC in vitro and in vivo in CD133+ cells, whereas the knockdown of miR-181 in CD133+ cells had the opposite effects. The direct downstream target of miR-181b was found to be the tumor suppressor gene TP53INP1, which is a pro-apoptotic stress-induced p53 target gene with both anti-proliferative and pro-apoptotic activities. Our study provided evidence that miR-181b can regulate CD133+ liver CSCs by silencing TP53INP1. More recently, Liu et al. have found that miR-130b (as well as miR-15b) was consistently and significantly up-regulated in HCC tissues, cell lines, and patient serum samples. Remarkably, the serum levels of these miRNAs were found to be significantly reduced after surgery, indicating that these circulating miRNAs originated from the tumor.

**miR-130b**

In our previous study, we have reported the preferential overexpression of miR-130b in CD133+ liver CSCs isolated from both HCC cell lines and freshly resected clinical samples. The ectopic expression of miR-130b was found to enhance chemo-resistance, self-renewal ability in vitro, and tumorigenicity in vivo in CD133+ cells, whereas the knockdown of miR-130b in CD133+ cells had the opposite effects. The direct downstream target of miR-130b was found to be the tumor suppressor gene TP53INP1, which is a pro-apoptotic stress-induced p53 target gene with both anti-proliferative and pro-apoptotic activities. Our study provided evidence that miR-130b can regulate CD133+ liver CSCs by silencing TP53INP1. More recently, Liu et al. have found that miR-130b (as well as miR-15b) was consistently and significantly up-regulated in HCC tissues, cell lines, and patient serum samples. Remarkably, the serum levels of these miRNAs were found to be significantly reduced after surgery, indicating that these circulating miRNAs originated from the tumor.

**let-7**

In addition to miR-181, the results reported by Meng et al. showed that let-7 was preferentially expressed in the Oct4+CD133+ liver CSC subset compared to HCC cells, HepG2 cells, or normal liver stem cells isolated from adult human liver tissue. The inhibition of let-7 increased the chemosensitivity of liver CSCs to sorafenib and doxorubicin, concomitant with an enhanced expression of two downstream targets, caspase-3 and SOCS1. They have also found IL-6, which is commonly overexpressed in HCC, to directly enhance the expression of let-7a and let-7b. let-7c and let-7f have been reported to be highly expressed in the serum samples of hepatitis B virus (HBV) carriers and HBV-positive HCC patients, respectively.

**miR-150**

miR-150 was also found to be preferentially expressed in CD133+ liver CSCs. miR-150 directly targeted c-Myb, and the overexpression of miR-150 resulted in reductions in cell proliferation and spheroid formation and a significant decrease in CD133+ cells. Moreover, the overexpression of miR-150 led to the down-regulation of the cell cycle regulator cyclin D1 and the cell survival regulator Bcl-2, resulting in cell cycle arrest and apoptosis in CD133+ cells. The levels of circulating miR-150 were also found to be at least 3-fold higher in HBV patients than in healthy individuals.

**miR-145**

miR-145 expression was found to be lower in HCC cancer stem cells derived from hepatocarcinoma cell line T3A-A3 than in the HCC cell line BEL-7402 or a normal liver sinusoidal endothelial cell line. The restoration of miR-145 in T3A-A3 cells resulted in senescence-like G0 cell cycle arrest, the inhibition of colony and spheroid formation, and the inhibition of tumor formation in nude mice. miR-145 overexpression led to a concomitant decrease in Oct4 expression, suggesting that miR-145 exerts its tumor-suppressive effect in HCC via modulation of this stem cell marker. To date, no study has reported the detection of miR-145 in the serum of HCC patients.
miR-199a-3p

In addition to being deregulated in liver CSC subsets, miRNAs can directly target liver CSC markers, as reported by Henry et al.[30], who have found that miR-199a-3p targets CD44 and reduces the proliferation and invasive capabilities of CD44+ liver CSCs in HCC cell lines. The detection of miR-199a-3p in the serum of HCC patients has not been reported yet.

Clinical Implications

Chronic HBV and hepatitis C virus (HCV) infection are major risk factors for HCC development. Thus, differential miRNA patterns that can distinguish between infection and tumor stages will be of high value for the diagnosis of the disease. Differential miRNA expression patterns in CSC and non-CSC subsets may further provide useful prognostic information regarding response to adjuvant therapy and survival and recurrence rates. miRNAs are very stable both in vitro and in vivo, and miRNA expression can be easily detected even in formalin-fixed, paraffin-embedded sections[34]. Circulating miRNAs can also be easily detected in human serum and plasma[35]. Thus, in addition to the current diagnostic methods for HCC, the joint detection of endogenous and circulating miRNAs in tissue and serum/plasma may further enhance the sensitivity and specificity of disease diagnosis and prognosis.

miRNAs can function as either tumor suppressors (antagomirs) or tumor initiators (oncomirs). The possibility of targeting miRNAs for therapeutic use in treating cancer patients is now being tested through either increasing the expression of antagomirs or adding inhibitors to block oncomirs. For antagonists, the use of the aden-associated virus (AAV) system to overexpress miR-26a or miR-124 in liver tumor-bearing tet-o-MYC;LAP-tTA mice was successful in inhibiting cancer cell growth, inducing tumor-specific apoptosis, and limiting disease progression without any toxic adverse effects[36,37]. The in vivo transfection of miR-124 using liposomes has also been reported to be a feasible technique for restoring physiologic miR-124 expression and suppressing HCC tumor growth, without any signs of toxicity, in a diethylnitrosamine (DEN)-treated tumor mice model[38]. For oncomirs, the administration of anti-miR-221 oligonucleotides to miR-221-overexpressing transgenic mice and the administration of a cholesterol-modified isoform of anti-miR-221 oligonucleotides in an orthotopic liver tumor xenograft model both resulted in a marked down-regulation of miR-221 and liver cancer progression[39,40].

miR-130b is a prime example of an miRNA that is deregulated in tissue and serum samples of HCC patients as well as in liver CSC subsets. In this case, endogenous and circulating miR-130b in the tissue and serum samples of HCC patients can be used for diagnosis as well as to predict recurrence and evaluate treatment response. Alternatively, miR-130b can also be used as a direct therapeutic target.

Conclusion

The understanding of the role of miRNAs in liver CSCs remains limited to date. There is an increasing demand for further investigation of the use of miRNAs in liver CSC subsets. Together with a better understanding of the pathogenesis of HCC and the mechanisms underlying liver CSC subsets, we believe that miRNAs, which target multiple genes and pathways in the complex cancer environment, can be used as therapeutic targets and as diagnostic and/or prognostic tools in HCC. Further studies in this emerging field are warranted.

Acknowledgments

Liver cancer stem cell studies in the laboratory is generously supported by grants from the Research Grant Council—General Research Fund (HKU 760911M and HKU 773412M), Research Grant Council—Collaborative Research Fund (CUHK8/CRF/11R, HKU3/CRF/11R and HKU7/CRF/09), and the University of Hong Kong Strategic Research Theme in Cancer.

Received: 2013-02-27; revised: 2013-05-07; accepted: 2013-05-07.

References

[1] Cancer facts and figures 2012. American Cancer Society. 2012. Accessed at http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2012.
[2] Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 2010,127:2893–2917.
[3] Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology, 2008,48:2047–2063.
[4] Qi J, Wang J, Katayama H, et al. Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma. Neoplasma, 2013,60:135–142.
[5] Tong CM, Ma S, Guan XY. Biology of hepatic cancer stem cells. J Gastroenterol Hepatol, 2011,26:1229–1237.
[6] Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med, 2011,17:313–319.
[7] Nagano H, Ishii H, Marubashi S, et al. Novel therapeutic target for cancer stem cells in hepatocellular carcinoma. J Hepatobiliary Pancreat Sci, 2012,19:600–605.
[8] Chiba T, Kita K, Zheng YW, et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell–like properties. Hepatology, 2006,44:240–251.
[9] Ma S, Chan KW, Hu L, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology, 2007,132:2542–2556.
[10] Ma S, Lee TK, Zheng BJ, et al. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene, 2008,27:1749–1758.
[11] Fan L, He F, Liu H, et al. CD133: a potential indicator for
Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog, 2011,50:136–142.

[22] Xu J, Wu C, Che X, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog, 2011,50:136–142.

[23] Li LM, Hu ZB, Zhou ZX, et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res, 2010,70:9798–9807.

[24] Ma S, Tang KH, Chan YP, et al. miR-130p promotes CD133(+)/ liver tumor-initiating cell growth and self-renewal via tumor protein 53–induced nuclear protein 1. Cell Stem Cell, 2010,7:694–707.

[25] Liu AM, Yao TJ, Wang W, et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open, 2012,2:e000825.

[26] Zhang J, Luo N, Luo Y, et al. microRNA-150 inhibits human CD133+ positive liver cancer stem cells through negative regulation of the transcription factor c-Myb. Int J Oncol, 2012,40:747–756.

[27] Jia Y, Liu H, Zhuang Q, et al. Tumorigenicity of cancer stem-like cells derived from hepatocarcinoma is regulated by microRNA-145. Oncol Rep, 2012,27:1865–1872.

[28] Henry JC, Park JK, Jiang J, et al. miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines. Biochem Biophys Res Commun, 2010,403:120–125.

[29] Sassen S, Miska EA, Caldas C. MicroRNA: implications for cancer. Virchows Arch, 2008,452:1–10.

[30] Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A, 2008,105:10513–10518.

[31] Hsu SH, Wang B, Kota J, et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest, 2012,122:2871–2883.

[32] Jia J, Chivukula RR, O’Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell, 2009,137:1005–1017.

[33] Hatziantoniou M, Polytarchou C, Aggelidou E, et al. An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell, 2011,147:1233–1247.

[34] Callegari E, Elamin BK, Giannone F, et al. Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology, 2012,56:1025–1033.

[35] Etheridge A, Lee I, Hood L, et al. Extracellular microRNA: a new source of biomarkers. Mutat Res, 2011,717:85–90.

[36] Meng F, Glaser SS, Francis H, et al. Functional analysis of microRNAs in human hepatocellular cancer stem cells. J Cell Mol Med, 2012,16:160–173.

[37] Zhao X, Yang Z, Li G, et al. The role and clinical implications of microRNAs in hepatocellular carcinoma. Sci China Life Sci, 2012,55:906–919.

[38] Ji J, Yamashita T, Budhu A, et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatocancer stem cells. Hepatology, 2009,50:472–480.

[39] Jia J, Yamashita T, Wang XW. Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma. Cell Biosci, 2011,1:4.

[40] Xu J, Wu C, Che X, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog, 2011,50:136–142.

[41] Li LM, Hu ZB, Zhou ZX, et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res, 2010,70:9798–9807.

[42] Ma S, Tang KH, Chan YP, et al. miR-130p promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53–induced nuclear protein 1. Cell Stem Cell, 2010,7:694–707.
Gui J, Tian Y, Wen X, et al. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci (Lond), 2011,120:183–193.

Liu WH, Yeh SH, Lu CC, et al. MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology, 2009,136:683–693.

Han ZB, Zhong L, Teng MJ, et al. Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation. Mol Oncol, 2012,6:445–457.

Karakatsanis A, Papaconstantinou I, Gazouli M, et al. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog, 2013,52:297–303.

Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology, 2007,133:647–658.

Zhu Q, Wang Z, Hu Y, et al. miR-21 promotes migration and invasion by the miR-21-PDCD4-AP-1 feedback loop in human hepatocellular carcinoma. Oncol Rep, 2012,27:1660–1668.

Zhang J, Yang Y, Yang T, et al. microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumorigenicity. Br J Cancer, 2010,103:1215–1220.

Yang X, Liang L, Zhang XF, et al. MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting IL-6-Stat3 pathway. Hepatology, 2013, in press.

Xiong Y, Fang JH, Yun JP, et al. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology, 2010,51:836–845.

Wang CM, Wang Y, Fan CG, et al. miR-29c targets TNF-αIP3, inhibits cell proliferation and induces apoptosis in hepatitis B virus–related hepatocellular carcinoma. Biochem Biophys Res Commun, 2011,411:586–592.

Yao J, Liang L, Huang S, et al. MicroRNA-30d promotes tumor invasion and metastasis by targeting Gaipah2 in hepatocellular carcinoma. Hepatology, 2010,51:846–852.

Li N, Fu H, Tie Y, et al. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma. Cancer Lett, 2009,275:44–53.

Li D, Liu X, Lin L, et al. MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem, 2011,286:36877–36885.

Petrelli A, Perra A, Schernhuber K, et al. Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression. Oncogene, 2012,31:4517–4526.

Zhang Y, Guo X, Xiong L, et al. MicroRNA-101 suppresses SOX9-dependent tumorigenicity and promotes favorable prognosis of human hepatocellular carcinoma. FEBS Lett, 2012,586:4362–4370.

Su H, Yang JR, Xu T, et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res, 2009,69:1135–1142.

Shen G, Jia H, Tai Q, et al. miR-106b downregulates adenomatous polyposis coli and promotes cell proliferation in human hepatocellular carcinoma. Carcinogenesis, 2013,34:211–219.

Zhang F, Liao YJ, Cai MY, et al. The putative tumour suppressor microRNA-124 regulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut, 2012, 61:278–289.

Br Q, Tang S, Xia L, et al. Ectopic expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF. PLoS One, 2012,7:e40169.

Kim JK, Noh JH, Jung KH, et al. Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. Hepatology, 2013,57:1055–1067.

Chen X, Zhang L, Zhang T, et al. Methylation-mediated repression of microRNA 129-2 enhances oncogenic SOX4 expression in HCC. Liver Int, 2013,33:476–486.

Wang W, Zhao LJ, Tan YX, et al. MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis, 2012,33:1113–1120.

Wong CC, Wong CM, Tung EK, et al. The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology, 2011,140:322–331.

Yang H, Fang F, Chang R, et al. MicroRNA-140-5p suppresses tumor growth and metastasis by targeting TGFBR1 and FGFr9 in hepatocellular carcinoma. Hepatology, 2013, in press.

Zhang X, Liu S, Hu T, et al. Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibrinectin expression. Hepatology, 2009,50:490–499.

Law PT, Ching AK, Chan AW, et al. miR-145 modulates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma. Carcinogenesis, 2012,33:1134–1141.

Ding J, Huang S, Wu S, et al. Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIa. Nat Cell Biol, 2010,12:390–399.

Han ZB, Chen HY, Fan JW, et al. Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. J Cancer Res Clin Oncol, 2012,138:153–161.

Wang J, Li J, Shen J, et al. MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma. BMC Cancer, 2012,12:227.

Li J, Fu H, Xu C, et al. miR-183 inhibits TGF-beta1–induced apoptosis by downregulation of PDCD4 expression in human hepatocellular carcinoma cells. BMC Cancer, 2010,10:354.

He Y, Cui Y, Wang W, et al. Hypermethylation of the hsa-miR-191 locus causes high expression of hsa-miR-191 and promotes the epithelial-to-mesenchymal transition in hepatocellular carcinoma.
Neoplasia, 2011,13:841–853.

[80] Xu C, Liu S, Fu H, et al. MicroRNA-193b regulates proliferation, migration and invasion in human hepatocellular carcinoma cells. Eur J Cancer, 2010,46:2828–2836.

[81] Xu T, Zhu Y, Xiong Y, et al. MicroRNA-195 suppresses tumorigenicity and regulates G0/S transition of human hepatocellular carcinoma cells. Hepatology, 2009,50:113–121.

[82] Tan S, Li R, Ding K, et al. miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway. FEBS Lett, 2011,585:2229–2234.

[83] Fornari F, Milazzo M, Chieco P, et al. miR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res, 2010,70:5184–5193.

[84] Shen Q, Cincinnati VR, Zhang X, et al. Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion. Mol Cancer, 2010,9:227.

[85] Ying Q, Liang L, Guo W, et al. Hypoxia-inducible microRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma. Hepatology, 2011,54:2064–2075.

[86] Shih TC, Tien YJ, Wen CJ, et al. MicroRNA-214 downregulation contributes to tumor angiogenesis by inducing secretion of the hepatoma-derived growth factor in human hepatoma. J Hepatol, 2012,57:584–591.

[87] Wang X, Chen J, Li F, et al. miR-214 inhibits cell growth in hepatocellular carcinoma through suppression of β-catenin. Biochem Biophys Res Commun, 2012,428:525–531.

[88] Chen PJ, Yeh SH, Liu WH, et al. Androgen pathway stimulates microRNA-216a transcription to suppress the tumor suppressor in lung cancer-1 gene in early hepatocarcinogenesis. Hepatology, 2012,56:632–643.

[89] Huang N, Lin J, Ruan J, et al. miR-219-5p inhibits hepatocarcinoma cell proliferation by targeting glypican-3. FEBS Lett, 2012,586:884–891.

[90] Zhang Y, Takahashi S, Tasaka A, et al. Involvement of microRNA-224 in cell proliferation, migration, invasion and anti-apoptosis in hepatocellular carcinoma. J Gastroenterol Hepatol, 2013,28:565–575.

[91] Zhou P, Jiang W, Wu L, et al. miR-301a is a candidate oncone that targets the homeobox gene Gax in human hepatocellular carcinoma. Dig Dis Sci, 2012,57:1171–1180.

[92] Dohi O, Yasui K, Gen Y, et al. Epigenetic silencing of miR-335 and its host gene MEST in hepatocellular carcinoma. Int J Oncol, 2013,42:411–418.

[93] Huang XH, Wang Q, Chen JS, et al. Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR-338 is downregulated. Hepatol Res, 2009,39:766–794.

[94] Fu X, Tan D, Hou Z, et al. miR-338-3p is down-regulated by hepatitis B virus X and inhibits cell proliferation by targeting the 3’-UTR region of Cyclin D1. Int J Mol Sci, 2012,13:8514–8539.

[95] Gu H, Guo X, Zou L, et al. Upregulation of microRNA-372 associates with tumor progression and prognosis in hepatocellular carcinoma. Mol Cell Biochem, 2013,375:23–30.

[96] Wu N, Liu X, Xu X, et al. MicroRNA-373, a new regulator of protein phosphatase 6, functions as an oncogene in hepatocellular carcinoma. FEBS J, 2011,278:2044–2054.

[97] He XX, Chang Y, Meng FY, et al. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene, 2012,31:3357–3369.

[98] Weng Z, Wang D, Zhao W, et al. microRNA-450a targets DNA methyltransferase 3a in hepatocellular carcinoma. Exp Ther Med, 2011,2:951–955.

[99] Zhang LY, Liu M, Li X, et al. miR-490-3p modulates cell growth and epithelial to mesenchymal transition of hepatocellular carcinoma cells by targeting endoplasmic reticulum-Golgi intermediate compartment protein 3 (ERGIC3). J Biol Chem, 2013,288:4035–4047.

[100] Fornari F, Milazzo M, Chieco P, et al. In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKNA1/p21, PTEN, AKT3 and TIMP2. J Pathol, 2012,227:275–285.

[101] Zhang W, Kong G, Zhang J, et al. MicroRNA-520b inhibits growth of hepatoma cells by targeting MEKK2 and cyclin D1. PLoS One, 2012,7:e31450.

[102] Zhang S, Shan C, Kong G, et al. MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-κB–inducing kinase (NIK). Oncogene, 2012,31:3607–3620.

[103] Tian Q, Liang L, Ding J, et al. MicroRNA-550a acts as a pro-metastatic gene and directly targets cytoplasmic polyadenylation element-binding protein 4 in hepatocellular carcinoma. PLoS One, 2012,7:e48958.

[104] Yang L, Ma Z, Wang D, et al. MicroRNA-602 regulating tumor suppressive gene RASSF1A is overexpressed in hepatitis B virus–infected liver and hepatocellular carcinoma. Cancer Biol Ther, 2010,9:803–808.

[105] El Tayebi HM, Hosny KA, Esmat G, et al. miR-615-5p is restrictedly expressed in cirrhotic and cancerous liver tissues and its overexpression alleviates the tumorigenic effects in hepatocellular carcinoma. FEBS Lett, 2012,586:3309–3316.

[106] Zhang JF, He ML, Fu WM, et al. Primate-specific microRNA-637 inhibits tumorigenesis in hepatocellular carcinoma by disrupting signal transducer and activator of transcription 3 signaling. Hepatology, 2011,54:2137–2148.

[107] Zeng ZL, Li FJ, Gao F, et al. Upregulation of miR-650 is correlated with down-regulation of ING4 and progression of hepatocellular carcinoma. J Surg Oncol, 2013,107:105–110.

[108] Zhang L, Yang L, Liu X, et al. MiR-657 promotes tumorigenesis in hepatocellular carcinoma by targeting transducin-like enhancer protein 1 through NF-κB pathways. Hepatology, 2013,57:1919–1930.